Patents by Inventor Martin Szelagiewicz

Martin Szelagiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11185545
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: November 30, 2021
    Assignee: Merck Patent GmbH
    Inventors: Rudolf Moser, Viola Groehn, Fritz Blatter, Martin Szelagiewicz, Ruth Boehni Stamm, Markus Ruettimann, Giuseppe Lapadula
  • Publication number: 20210283136
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 16, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Publication number: 20210277006
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 9, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Publication number: 20210275533
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 9, 2021
    Applicant: Merck Patent GmbH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Publication number: 20210269444
    Abstract: The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 2, 2021
    Applicant: Merck Patent GmbH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Publication number: 20210220366
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: July 22, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ
  • Patent number: 11066408
    Abstract: The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the sodium is from 1:0.5 to 1:1.5 and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the organic base is 1:0.5 to 1:1.5 and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Rudolf Moser, Viola Groehn, Fritz Blatter, Martin Szelagiewicz, Ruth Boehni Stamm, Markus Ruettimann, Giuseppe Lapadula
  • Publication number: 20210107902
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 15, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Fritz BLATTER, Martin SZELAGIEWICZ, Ruth BOEHNI STAMM, Markus RUETTIMANN
  • Publication number: 20210002227
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 7, 2021
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Publication number: 20200148644
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: January 13, 2020
    Publication date: May 14, 2020
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Publication number: 20200039982
    Abstract: The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the sodium is from 1:0.5 to 1:1.5 and the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to the organic base is 1:0.5 to 1:1.5 and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.
    Type: Application
    Filed: March 28, 2018
    Publication date: February 6, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Fritz BLATTER, Martin SZELAGIEWICZ, Ruth BOEHNI STAMM, Markus RUETTIMANN, Giuseppe LAPADULA
  • Publication number: 20200030333
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.
    Type: Application
    Filed: March 28, 2018
    Publication date: January 30, 2020
    Applicant: Merck Patent GmbH
    Inventors: Rudolf MOSER, Viola GROEHN, Fritz BLATTER, Martin SZELAGIEWICZ, Ruth BOEHNI STAMM, Markus RUETTIMANN, Giuseppe LAPADULA
  • Publication number: 20190256469
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: May 1, 2019
    Publication date: August 22, 2019
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Publication number: 20180346425
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: August 3, 2018
    Publication date: December 6, 2018
    Applicant: Nissan Chemical Industries, Ltd.
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Publication number: 20180230140
    Abstract: The present invention primarily relates to multicomponent crystals comprising a compound of formula 1 and a second compound selected from the group consisting of menthol and vanillin. The invention is further related to pharmaceutical compositions comprising such multicomponent crystals. Furthermore, the invention relates to processes for preparing said multicomponent crystals. The invention also relates to several aspects of using said multicomponent crystals or pharmaceutical compositions to treat a disease.
    Type: Application
    Filed: June 24, 2015
    Publication date: August 16, 2018
    Applicant: BASF SE
    Inventors: Martin VIERTELHAUS, Tiziana CHIODO, Beate SALVADOR, Marcus VOSSEN, Andreas HAFNER, Tobias HINTERMANN, Martin SZELAGIEWICZ, Fritz BLATTER
  • Patent number: 10045998
    Abstract: Combinations of (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: August 14, 2018
    Assignee: BASF SE
    Inventors: Tiziana Chiodo, Beate Salvador, Marcus Vossen, Andreas Hafner, Tobias Hintermann, Martin Szelagiewicz, Fritz Blatter, Martin Viertelhaus, Walter Weishaar
  • Patent number: 9884857
    Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: February 6, 2018
    Assignee: BASF SE
    Inventors: Andreas Hafner, Fritz Blatter, Martin Szelagiewicz, Bernd Siebenhaar, Tiziana Chiodo, Tobias Hintermann, Beate Salvador, Marcus Vossen
  • Publication number: 20180029987
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 1, 2018
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Patent number: 9567317
    Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: February 14, 2017
    Assignee: BASF SE
    Inventors: Tiziana Chiodo, Andreas Hafner, Tobias Hintermann, Beate Salvador, Martin Szelagiewicz, Fritz Blatter, Eva Roedel, Marcus Vossen
  • Patent number: 9556164
    Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: January 31, 2017
    Assignee: BASF SE
    Inventors: Andreas Hafner, Fritz Blatter, Martin Szelagiewicz, Bernd Siebenhaar, Tiziana Chiodo, Tobias Hintermann, Beate Salvador, Marcus Vossen